Clinical Pharmacology and Pharmacy

Clinical Pharmacology and Pharmacy, research focus oncology/ hematology

Our pharmaceutic research focuses on precision medicine, aiming to improve efficacy and reduce toxicity of anticancer drug therapy. We study adherence, quantitative pharmacology (pharmacometrics) to predict interpatient variability for model-informed precision dosing, sustainability, compounding and logistics and palliative treatments.

Group members

Prof. Dr E.L.(Noortje) Swart (principal investigator)
Prof. Dr J. G. (Jacqueline) Hugtenburg (principal investigator)
Dr. I.H. (Imke) Bartelink (principal investigator)
Dr. M. (Mirjam) Crul
Dr. P.M. (Pierre) Bet
Dr. L.G.W. (Linda) Franken (Post-doc)
MSc. M.M. (Medhat) Said (PhD-student)
PharmD S (Susanne) van der Gaag (PhD-student)
PharmD AJ (Anne-Jaël) Elskamp (PhD-student)
MSc. T.G. (Tamara) Jordens (PhD-student)
MSc. R. (Reyhane) Alinezhad (PhD-student)

Key publications

Bartelink IH, van de Stadt EA, Leeuwerik AF, Thijssen VLJL, Hupsel JRI, van den Nieuwendijk JF, Bahce I, Yaqub M, Hendrikse NH. Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients. Pharmaceuticals (Basel). 2022 Jun 27;15(7):796. PMID: 35890095

Bognàr T, Garcia-Rosa M, Lalmohamed A, Güngör T, Hauri-Hohl MM, Prockop SE, Oram LM, Pai SY, Brooks J, Savic RM, Dvorak CC, Long-Boyle JR, Krajinovic M, Bittencourt H, Teyssier AC, Theoret Y, Martinez C, Egberts TCG, Morales E, Slatter MA, Cuvelier GDE, Chiesa R, Wynn R, Coussons M, Cicalese MP, Ansari M, Long SE, Ebens CL, Lust H, Chaudhury S, Nath CE, Shaw PJ, Keogh SJ MBBS, FRACP, van der Stoep E, Bredius RG, Lindemans CA, Boelens JJ, Bartelink IH. Association of Busulfan Exposure and Outcomes after HCT for Patients with an Inborn Error of Immunity. Blood Adv. 2024 Jul 29:bloodadvances.2024013275. PMID: 39074263

Tromp VNMF, Timmers L, Koningen L, Janssen JJWM, Westerweel PE, Geelen IGP, de Jong J, Beckeringh JJ, Boons CCLM, Hugtenburg JG. Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views. Leuk Lymphoma. 2021 Mar;62(3):649-658. doi: 10.1080/10428194.2020.1839655. Epub 2020 Nov 6. PMID: 33153332.

En-Nasery-de Heer S, Tromp VNMF, Westerman MJ, Konings I, Beckeringh JJ, Boons CLM, Timmers L, Hugtenburg JG. Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study. Eur J Cancer Care (Engl). 2022 Nov;31(6):e13749. doi: 10.1111/ecc.13749. Epub 2022 Oct 27. PMID: 36300863; PMCID: PMC9786726.

Güngören MH, Romeijn S, Dijkstra JA, Crul M. Investigating the Impact of Drone Transport on the Stability of Monoclonal Antibodies for Inter-Hospital Transportation. I. 2024; 113, 7, p. 1816-1822 7 p. doi: 10.1016/j.xphs.2024.04.002

Huntjens DW, Vanhommerig JW, van de Veen W, . Exclusion of Ranitidine From Premedication Regimens During Paclitaxel Treatment. JAMA Oncology 2024;;10(1):131-132 doi: 10.1001/jamaoncol.2023.4821.

Ganesh, S. V., Beunk, L., Nikolik, B., van der Weide, J. & Bet, P. M., Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype. 1 Oct 2021, In: Therapeutic drug monitoring. 43, 5, p. 672-680 9 p.

Martens, F. K., Huntjens, D. W., Rigter, T., Bartels, M., Bet, P. M. & Cornel, M. C., DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice. 28 Jan 2020, In: Frontiers in pharmacology. 10, January, p. 1-10 10 p., 1609.

Contact

Contact one of our researchers, if necessary he/she can refer you to the appropriate specialist.

Keywords

Cancer Center Amsterdam